Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

Opinion|Videos|March 27, 2025

FDA-Approved Treatments for BCG-Unresponsive NMIBC

Author(s)Chad A. Reichard, MD , Karim Chamie, MD, MSHS , R. Jonathan Henderson, MD

Experts briefly discuss 3 new FDA-approved treatments for patients who are unresponsive to bacille Calmette-Guérin (BCG) in the last 5 years—pembrolizumab, nogapendekin alfa inbakicept-pmln, and nadofaragene firadenovec—highlighting how each is administered, and share their impressions of the safety and efficacy of these agents.

Episodes in this series

EP. 1 Standard of Care and Intravesical Chemotherapy in NMIBC

EP. 1 Standard of Care and Intravesical Chemotherapy in NMIBC

EP. 2 BCG for treatment of NMIBC

EP. 2 BCG for treatment of NMIBC

EP. 3 Cystectomy in NMIBC

EP. 3 Cystectomy in NMIBC

EP. 4 New Intravesical Delivery Systems and TAR-200 in NMIBC

EP. 4 New Intravesical Delivery Systems and TAR-200 in NMIBC

EP. 5 TAR-200 Efficacy and Safety in High-Risk BCG- Unresponsive NMIBC (SunRISe-1)

EP. 5 TAR-200 Efficacy and Safety in High-Risk BCG- Unresponsive NMIBC (SunRISe-1)

EP. 6 TAR-200 Clinical Development Program in NMIBC

EP. 6 TAR-200 Clinical Development Program in NMIBC

EP. 7 Other Investigational Drug Delivery Systems in NMIBC

EP. 7 Other Investigational Drug Delivery Systems in NMIBC

EP. 8 Cretostimogene Grenadenorepvec and Integration of Novel Therapies in High-Risk BCG-Unresponsive NMIBC

EP. 8 Cretostimogene Grenadenorepvec and Integration of Novel Therapies in High-Risk BCG-Unresponsive NMIBC

EP. 9 FDA-Approved Treatments for BCG-Unresponsive NMIBC

EP. 9 FDA-Approved Treatments for BCG-Unresponsive NMIBC

EP. 10 Use and Sequencing of Novel Treatments in NMIBC

EP. 10 Use and Sequencing of Novel Treatments in NMIBC

EP. 11 Communication of Treatment Options for High-Risk NMIBC

EP. 11 Communication of Treatment Options for High-Risk NMIBC

EP. 12 Checkpoint Inhibitors for Treatment of NMIBC

EP. 12 Checkpoint Inhibitors for Treatment of NMIBC

EP. 13 Unmet Needs in NMIBC

EP. 13 Unmet Needs in NMIBC

EP. 14 Operationalizing TAR-200 and Other Delivery Systems in Practice

EP. 14 Operationalizing TAR-200 and Other Delivery Systems in Practice

EP. 15 Patient Communication and Treatment Adherence in NMIBC

EP. 15 Patient Communication and Treatment Adherence in NMIBC

EP. 16 Uptake of New Treatments in Urology Practice

EP. 16 Uptake of New Treatments in Urology Practice

EP. 17 Final Thoughts and Clinical Trials in NMIBC

EP. 17 Final Thoughts and Clinical Trials in NMIBC

Video content above is prompted by the following:

Three new treatments for patients who are unresponsive to BCG were FDA approved in the last 5 years. Briefly discuss each of the following approved therapies and how are they are administered.
Pembrolizumab, nogapendekin alfa inbakicept-pmln, and nadofaragene firadenovec
What are your impressions of the safety and efficacy of these agents?

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Latest CME

DSUI Urology on the Beach

In-Person Event

DSUI Urology on the Beach

January 16-18, 2026

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Texas

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Texas

Jeremie Calais, MD, PhD; Qian Qin, MD

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment

February 23, 2026

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Aaron D. Berger, MD

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Jason M. Hafron, MD

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Stacy Loeb, MD, MSc, PhD (Hon)

Trending on Urology Times

Dosing begins in trial of alpha radioligand therapy for mCRPC

Novel tool may help predict early PSA response to ARPIs in mHSPC

Fed Ghali, MD, highlights trial of consolidative local therapy following EV/P

RCMIGI trial supports feasibility of reduced margins in image-guided prostate radiotherapy

Mark Tyson, MD, highlights ADVANCED-2 trial in BCG-naïve NMIBC